104 related articles for article (PubMed ID: 27763956)
1. Concentration of D-dimers in Bile-a Novel Marker of Pancreatic Cancer Enhancing Accuracy of Standard CA19-9 Measurement: Dual Test Hypothesis.
Durczynski A; Kumor A; Grzelak P; Strzelczyk M; Hogendorf P; Poznanska G; Skulimowski A; Szymanski D; Strzelczyk J
Pancreas; 2017 Jan; 46(1):e9-e10. PubMed ID: 27763956
[No Abstract] [Full Text] [Related]
2. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2016 Mar; 16(4):537-43. PubMed ID: 27002756
[TBL] [Abstract][Full Text] [Related]
4. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.
Su SB; Qin SY; Chen W; Luo W; Jiang HX
World J Gastroenterol; 2015 Apr; 21(14):4323-33. PubMed ID: 25892884
[TBL] [Abstract][Full Text] [Related]
5. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.
Kuwatani M; Kawakami H; Kubota Y; Kawakubo K; Ito YM; Togo S; Ikeda T; Kusama K; Kobayashi Y; Murata T; Sakamoto N
Pancreatology; 2019 Jun; 19(4):569-577. PubMed ID: 31031206
[TBL] [Abstract][Full Text] [Related]
6. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
[TBL] [Abstract][Full Text] [Related]
9. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection.
Fahrmann JF; Schmidt CM; Mao X; Irajizad E; Loftus M; Zhang J; Patel N; Vykoukal J; Dennison JB; Long JP; Do KA; Zhang J; Chabot JA; Kluger MD; Kastrinos F; Brais L; Babic A; Jajoo K; Lee LS; Clancy TE; Ng K; Bullock A; Genkinger J; Yip-Schneider MT; Maitra A; Wolpin BM; Hanash S
Gastroenterology; 2021 Mar; 160(4):1373-1383.e6. PubMed ID: 33333055
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
[TBL] [Abstract][Full Text] [Related]
11. p53 protein expression and CA19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis.
Mu DQ; Wang GF; Peng SY
World J Gastroenterol; 2003 Aug; 9(8):1815-8. PubMed ID: 12918127
[TBL] [Abstract][Full Text] [Related]
12. Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis.
Deng T; Yuan Y; Zhang C; Zhang C; Yao W; Wang C; Liu R; Ba Y
Cell Physiol Biochem; 2016; 39(5):1716-1722. PubMed ID: 27639768
[TBL] [Abstract][Full Text] [Related]
13. Detection of pancreatic adenocarcinoma using circulating fragments of fibrinogen.
Ward DG; Wei W; Buckels J; Taha AM; Hegab B; Tariciotti L; Salih R; Qi YQ; Martin A; Johnson PJ
Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1358-63. PubMed ID: 20555269
[TBL] [Abstract][Full Text] [Related]
14. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
15. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
[TBL] [Abstract][Full Text] [Related]
16. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma.
Liao WC; Wu MS; Wang HP; Tien YW; Lin JT
Pancreas; 2009 May; 38(4):422-6. PubMed ID: 19214136
[TBL] [Abstract][Full Text] [Related]
17. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit?
Bedi MM; Gandhi MD; Jacob G; Lekha V; Venugopal A; Ramesh H
Indian J Gastroenterol; 2009; 28(1):24-7. PubMed ID: 19529898
[TBL] [Abstract][Full Text] [Related]
18. The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis.
Dranka-Bojarowska D; Lekstan A; Olakowski M; Jablonska B; Lewinski A; Musialski P; Sobczyk W; Kapalka A; Lampe P
J Physiol Pharmacol; 2015 Oct; 66(5):653-63. PubMed ID: 26579571
[TBL] [Abstract][Full Text] [Related]
19. Multianalyte profiling of serum cytokines for detection of pancreatic cancer.
Zeh HJ; Winikoff S; Landsittel DP; Gorelik E; Marrangoni AM; Velikokhatnaya L; Winans MT; Lee K; Moser A; Bartlett D; Lotze MT; Siegfried JM; Whitcomb D; Papacristou G; Slivka A; Bigbee WL; Lokshin AE
Cancer Biomark; 2005; 1(6):259-69. PubMed ID: 17192050
[TBL] [Abstract][Full Text] [Related]
20. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
